066700 — THERAGEN ETEX CO Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapContrarian

Market Cap
KR₩95bn
Enterprise Value
KR₩128bn
Revenue
KR₩250bn

Annual income statement for THERAGEN ETEX CO, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	R2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	143,023	166,567	190,769	216,470	249,625
Cost of Revenue
Gross Profit	45,586	61,175	77,868	100,668	125,981
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	149,613	175,648	179,746	204,906	231,786
Operating Profit	-6,591	-9,081	11,023	11,564	17,839
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-8,340	-12,676	13,855	32,747	-43,159
Provision for Income Taxes
Net Income After Taxes	-9,079	-11,385	12,428	29,679	-40,141
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-8,968	-11,854	9,561	26,211	-40,985
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-8,968	-11,854	9,561	26,211	-40,985
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-278	-333	249	850	-1,405
Dividends per Share